- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Dose Escalation Study of High Dose Etoposide in Autologous Hematopoietic Stem Cell Transplantation
-
- TANIGUCHI Shuichi
- Department of Internal Medicine
-
- YAMASAKI Kazuo
- Department of Internal Medicine
-
- OHNO Yuju
- Department of Internal Medicine
-
- HAGIMOTO Naoki
- Department of Internal Medicine
-
- HIGUCHI Kazuyuki
- Department of Internal Medicine
-
- KATOH Masato
- Department of Surgery, Hamanomachi General Hospital
-
- ASAYAMA Ryokichi
- Department of Internal Medicine
-
- TAKITA Atsushi
- Department of Internal Medicine
-
- HYODO Sadao
- Department of Internal Medicine
-
- HARADA Mine
- The First Department of Internal Medicine, Kyushu University
-
- NIHO Yoshiyuki
- The First Department of Internal Medicine, Kyushu University
Bibliographic Information
- Other Title
-
- 自己造血幹細胞移植におけるエトポシド大量投与の試み
- —Dose Escalation Study—
Search this article
Description
Eight cases with poor prognosis hematological malignancies (non-Hodgkin lymphoma, 6 cases; acute non-lymphocytic leukemia, 2 cases) and nine cases with non-hematological malignancies were treated with high dose etoposide (VP16) containing regimen followed by autologous hemopoietic stem cell transplantation. Results were as follows; 1) all of three chemotharapy sensitive relapse patients with hematological malignancies continue complete remission without any cyto-reductive therapy 2) one of four refractory relapse patients continue remission 3) partial anti-tumor effect was noted in non-hematological malignancies, however, only two cases continue complete remission. Remission duration of other responders was not so long. The results disclosed the dose-limiting factor of high-dose VP16 therapy as reversible stomatitis with no related mortality, and maximal tolerated dose appears to be 60 mg/kg over 72 hr with 45 mg/kg as a safe and recommended therapeutic dose in future clinical trial. The clinical effect of dose escalation was not clearly demonstrated.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 34 (7), 809-814, 1993
The Japanese Society of Hematology
